Found 423 clinical trials
A Study of Opaganib in Coronavirus Disease 2019 Pneumonia
Opaganib, a sphingosine kinase-2 (SphK2) inhibitor, has been broadly tested in Phase I/II studies. Extensive nonclinical data indicates both anti-viral and anti-inflammatory activity via selective SphK2 inhibition which may prove beneficial for treating COVID-19 infection and resulting pneumonia. This proof of concept study will take place in the US and …
- 0 views
- 16 Feb, 2024
- 5 locations
Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine
In this trial, a total of 50 subjects were recruited; the test vaccines were divided into 3 groups, low-dose vaccine groups, high-dose vaccine groups, and placebo groups. The first-stage randomized participants in the low-dose group (20 cases) and the placebo group (5 cases) were evaluated for 7 days. After the …
- 0 views
- 16 Feb, 2024
- 1 location
A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19
Primary Objective: To evaluate the effect of SAR443122 relative to the control arm on the hyperinflammatory state as measured by C-reactive protein (CRP) levels in adult patients hospitalized with severe COVID-19 Secondary Objectives: To evaluate the time to onset of effect of SAR443122 relative to the control arm on the …
- 0 views
- 05 Aug, 2020
ICBT for Mental Health Problems Related to the Coronavirus Pandemic
The study seeks to investigate the effects of a guided internet-based cognitive behavioral therapy (ICBT) programme a on adult mental health problems related to the current coronavirus pandemic. ICBT will be compared to a wait-list control group. Participants will be recruited in Sweden with a nationwide recruitment.
- 0 views
- 05 Aug, 2020
Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID 19)
This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC) treatment, in patients with Coronavirus disease 2019 (COVID 19)
- 0 views
- 05 Aug, 2020
Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19)
The objectives of this study are to evaluate the safety, tolerability and efficacy of AT-527 in older subjects (ages 45-80 years) with moderate COVID-19 and risk factors for poor outcomes (such as obesity (BMI>30), hypertension, diabetes or asthma). Eligible subjects will be randomized to blinded AT-527 (nucleotide analog) tablets or …
- 0 views
- 16 Feb, 2024
- 10 locations
Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Participants With Coronavirus Disease (COVID-19)
The primary objective of the study is to determine if Prolastin plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day 15 or who are dependent on invasive mechanical ventilation on Day 15 versus SMT alone in hospitalized participants with …
- 0 views
- 05 Aug, 2020
Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease
This is a randomized controlled trial of the efficacy and safety evaluation of oral administration of Bromhexine hydrochloride for the prevention of SARS-CoV-2 infection and COVID-19 disease in medical personnel assisting patients with a new coronavirus disease
- 0 views
- 16 Feb, 2024
- 1 location
Safety Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.
The study will be a randomized, partially-blinded, prime-boost, staggered dose-escalation Phase 1 study intended to assess the safety, tolerability, and immunogenicity of the Coronavirus-Like Particle COVID-19 Vaccine at three dose levels (3.75 g, 7.5 g, and 15 g VLP) unadjuvanted or adjuvanted with either CpG 1018 or AS03 in healthy …
- 0 views
- 01 Feb, 2023
- 2 locations
A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients
The primary purpose is to evaluate the safety and tolerability of OP-101 and secondary purpose is to determine the effect of OP-101 reducing proinflammatory cytokines after a single dose in severe COVID-19 Patients.
- 0 views
- 05 Aug, 2020